Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 423174, 10 pages
http://dx.doi.org/10.1155/2014/423174
Research Article

Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients

1INSERM, U1040, F-34197, Institute of Research in Biotherapy, CHU Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier Cedex, France
2CHU Montpellier, Institute of Research in Biotherapy, Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier, France
3Université Montpellier 1, UFR Médecine, Montpellier, 80 Avenue Augustin Fliche, 34285 Montpellier, France
4Institut de Biologie Computationnelle, Université Montpellier 2, 2 Place Eugène Bataillon, 34095 Montpellier Cedex 5, France

Received 26 September 2013; Revised 18 March 2014; Accepted 20 March 2014; Published 5 May 2014

Academic Editor: Carlo Visco

Copyright © 2014 Elias Bou Samra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Chiorazzi, K. R. Rai, and M. Ferrarini, “Chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 352, no. 8, pp. 804–815, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Stamatopoulos, C. Belessi, C. Moreno et al., “Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations,” Blood, vol. 109, no. 1, pp. 259–270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Z. Rassenti, L. Huynh, T. L. Toy et al., “ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 351, no. 9, pp. 893–901, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Z. Rassenti, S. Jain, M. J. Keating et al., “Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia,” Blood, vol. 112, no. 5, pp. 1923–1930, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. Mead, S. A. Irvine, and D. P. Ramji, “Lipoprotein lipase: structure, function, regulation, and role in disease,” Journal of Molecular Medicine, vol. 80, no. 12, pp. 753–769, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Orchard, R. E. Ibbotson, Z. Davis et al., “ZAP-70 expression and prognosis in chronic lymphocytic leukaemia,” The Lancet, vol. 363, no. 9403, pp. 105–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Josefsson, C. H. Geisler, H. Leffers et al., “CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia,” Blood, vol. 109, no. 11, pp. 4973–4979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Herling, K. A. Patel, N. Weit et al., “High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia,” Blood, vol. 114, no. 21, pp. 4675–4686, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Stamatopoulos, N. Meuleman, B. Haibe-Kains et al., “microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification,” Blood, vol. 113, no. 21, pp. 5237–5245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Zucchetto, R. Bomben, M. Dal Bo et al., “A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia,” Journal of Cellular Physiology, vol. 207, no. 2, pp. 354–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Rodríguez, R. Villuendas, L. Yáñez, M. E. Gómez, R. Díaz, and M. Pollán, “Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation,” Leukemia, vol. 21, pp. 1984–1991, 2007. View at Google Scholar
  13. D. Kienle, A. Benner, C. Läufle, D. Winkler, C. Schneider, and A. Bühler, “Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia,” Haematologica, vol. 95, pp. 102–109, 2010. View at Google Scholar
  14. B. Stamatopoulos, N. Meuleman, C. de Bruyn et al., “A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients,” PLoS ONE, vol. 5, no. 9, Article ID e12780, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Herold, V. Jurinovic, K. H. Metzeler et al., “An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia,” Leukemia, vol. 25, no. 10, pp. 1639–1645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. H.-Y. Chuang, L. Rassenti, M. Salcedo, K. Licon, A. Kohlmann, and T. Haferlach, “Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression,” Blood, vol. 120, pp. 2639–2649, 2012. View at Google Scholar
  17. T. Herold, V. Jurinovic, M. Mulaw et al., “Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20,” Genes Chromosomes and Cancer, vol. 50, no. 7, pp. 546–558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Kassambara, D. Hose, J. Moreaux et al., “Genes with a spike expression are clustered in chromosome (sub) bands and spike (sub) bands have a powerful prognostic value in patients with multiple Myeloma,” Haematologica, vol. 97, no. 4, pp. 622–630, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Bret, B. Klein, and J. Moreaux, “Gene expression-based risk score in diffuse large B-cell lymphoma,” Oncotarget, vol. 3, pp. 1700–1710, 2013. View at Google Scholar
  21. R. Rosenquist, D. Cortese, S. Bhoi, L. Mansouri, and R. Gunnarsson, “Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?” Leukemia & Lymphoma, vol. 54, pp. 2351–2364, 2013. View at Google Scholar
  22. M. B. van't Veer, A. M. Brooijmans, A. W. Langerak et al., “The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia,” Haematologica, vol. 91, no. 1, pp. 56–63, 2006. View at Google Scholar · View at Scopus
  23. J. Nautiyal, J. H. Steel, M. R. Mane, O. Oduwole, A. Poliandri, and X. Alexi, “The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals,” Development, vol. 140, pp. 1079–1089, 2013. View at Google Scholar
  24. T. Reya, M. O'Riordan, R. Okamura et al., “Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism,” Immunity, vol. 13, no. 1, pp. 15–24, 2000. View at Google Scholar · View at Scopus
  25. E. A. Ranheim, H. C. K. Kwan, T. Reya, Y.-K. Wang, I. L. Weissman, and U. Francke, “Frizzled 9 knock-out mice have abnormal B-cell development,” Blood, vol. 105, no. 6, pp. 2487–2494, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Roose, G. Huls, M. van Beest et al., “Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1,” Science, vol. 285, no. 5435, pp. 1923–1926, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Huls, J. van Es, H. Clevers, G. de Haan, and R. van Os, “Loss of Tcf7 diminishes hematopoietic stem/progenitor cell function,” Leukemia, vol. 7, pp. 1613–1614, 2013. View at Google Scholar
  28. T. Zenz, A. Kröber, K. Scherer et al., “Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up,” Blood, vol. 112, no. 8, pp. 3322–3329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Bou Samra, B. Klein, T. Commes, and J. Moreaux, “Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients,” Oncotarget, vol. 3, pp. 824–832, 2012. View at Google Scholar
  30. J. Moreaux, B. Klein, R. Bataille et al., “A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines,” Haematologica, vol. 96, no. 4, pp. 574–582, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Sevov, R. Rosenquist, and L. Mansouri, “RNA-based markers as prognostic factors in chronic lymphocytic leukemia,” Expert Review of Hematology, vol. 5, no. 1, pp. 69–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Docquier, P.-O. Harmand, S. Fritsch, M. Chanrion, J.-M. Darbon, and V. Cavaillès, “The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes,” Clinical Cancer Research, vol. 16, no. 11, pp. 2959–2970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Docquier, P. Augereau, M. Lapierre, P.-O. Harmand, E. Badia, and J.-S. Annicotte, “The RIP140 gene is a transcriptional target of E2F1,” PLoS ONE, vol. 7, Article ID e35839, 2012. View at Google Scholar
  34. C. D. Baldus, S. Liyanarachchi, K. Mrózek et al., “Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 11, pp. 3915–3920, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Haslinger, N. Schweifer, S. Stilgenbauer et al., “Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status,” Journal of Clinical Oncology, vol. 22, no. 19, pp. 3937–3949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Q. Wu, M. Seay, V. P. Schulz et al., “Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell line,” PLoS Genetics, vol. 8, no. 3, Article ID e1002565, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Y. Logan and R. Nusse, “The Wnt signaling pathway in development and disease,” Annual Review of Cell and Developmental Biology, vol. 20, pp. 781–810, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Lu, Y. Zhao, R. Tawatao et al., “Activation of the Wnt signaling pathway in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3118–3123, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. P. F. S. Etet, L. Vecchio, and A. H. Nwabo Kamdje, “Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways?” Cellular Signalling, vol. 24, no. 7, pp. 1433–1443, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Ge and X. Wang, “Role of Wnt canonical pathway in hematological malignancies,” Journal of Hematology & Oncology, vol. 3, no. 33, 2010. View at Google Scholar
  41. B. L. Abbott, “Chronic lymphocytic leukemia: recent advances in diagnosis and treatment,” The Oncologist, vol. 11, no. 1, pp. 21–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Weeda, I. Donker, J. de Wit et al., “Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence,” Current Biology, vol. 7, no. 6, pp. 427–439, 1997. View at Google Scholar · View at Scopus
  43. R. Geleziunas, A. McQuillan, A. Malapetsa et al., “Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustard,” Journal of the National Cancer Institute, vol. 83, no. 8, pp. 557–564, 1991. View at Google Scholar · View at Scopus
  44. P. H. Clingen, I. U. de Silva, P. J. McHugh et al., “The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136,” Nucleic Acids Research, vol. 33, no. 10, pp. 3283–3291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Pepper, H. Lowe, C. Fegan et al., “Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells,” British Journal of Cancer, vol. 97, no. 2, pp. 253–259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. Barret, M. Cadou, and B. T. Hill, “Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid,” Biochemical Pharmacology, vol. 63, no. 2, pp. 251–258, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. B. S. King, K. L. Cooper, K. J. Liu, and L. G. Hudson, “Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair,” The Journal of Biological Chemistry, vol. 287, pp. 39824–39833, 2012. View at Google Scholar
  48. L. Michaux, I. Wlodarska, K. Rack et al., “Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in “unmutated” B-CLL,” Leukemia, vol. 19, no. 1, pp. 77–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. J. A. Burger, M. Burger, and T. J. Kipps, “Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells,” Blood, vol. 94, no. 11, pp. 3658–3667, 1999. View at Google Scholar · View at Scopus
  50. J. A. Burger, N. Tsukada, M. Burger, N. J. Zvaifler, M. Dell'Aquila, and T. J. Kipps, “Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1,” Blood, vol. 96, no. 8, pp. 2655–2663, 2000. View at Google Scholar · View at Scopus
  51. A. M. McCaig, E. Cosimo, M. T. Leach, and A. M. Michie, “Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12,” PLoS ONE, vol. 7, Article ID e48929, 2012. View at Google Scholar
  52. M. Sivina, E. Hartmann, T. J. Kipps et al., “CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia,” Blood, vol. 117, no. 5, pp. 1662–1669, 2011. View at Publisher · View at Google Scholar · View at Scopus